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medication, 13% switched medication, 10% both delayed and stopped medication
while 9% of members both switched and delayed medication. The data show people
who experienced the doughnut hole are 1.3 times more likely to switch, 2 times more
likely to delay, 3 times more likely to switch and delay, and 4.7 times more likely to 
switch, stop, and delay their prescription medications. CONCLUSIONS: The results 
of the study suggest that the doughnut hole is a factor in alteration of prescription 
fulﬁ llment decisions by Part D members. Because patient non-compliance of medica-
tions may result in mortality it is important that the Medicare Part D standard pre-
scription drug plan be designed to limit excessive ﬁ nancial burden to members based
on spending levels.
PIH49
HORMONE REPLACEMENT THERAPY: AN ANALYSIS FOCUSING ON
DRUG CLAIMS BY FEMALE SENIORS 2000 TO 2007
Gaucher M, Hunt J
Canadian Institute for Health Information, Ottawa, ON, Canada
OBJECTIVES: This analysis was intended to identify trends in Hormone Replacement 
Therapy (HRT) use in female seniors on public drug programs in 5 Canadian provinces 
between 2001–2002 and 2006–2007. METHODS: Claims level data were analyzed
for female seniors on public drug programs in Alberta, Saskatchewan, Manitoba, New 
Brunswick and Nova Scotia. The analysis included calculation of the proportion of 
female seniors on these programs using HRT, and also examined trends in the dosage
and type of therapy used. RESULTS: The rate of HRT use among female seniors in
the 5 provinces dropped from 13.9% in 2001–2002 to 5.2% in 2006–2007. The
decrease in combination HRT use (24.9% per year) was greater than the decrease in 
estrogen only HRT use (14.7% per year). The vast majority of female seniors still 
using HRT in 2006–2007 were on estrogen-only regimens (84%). Of women using 
the higher (0.625 mg) dose in 2001–2002 and still using HRT in 2006–2007, 37%
had switched to the lower (0.3 mg) dose. CONCLUSIONS: This analysis provides
insight into how new evidence affected HRT use in Canadian female seniors. The 
decline in HRT use observed was consistent with the results of other studies examining 
use during this time period. The majority of women still using HRT at the end of the 
study period were on estrogen-only regimens, with over a third of these women using
a lower dose.
PIH50
USE OF CATEGORY X AND D API’S DURING PREGNANCY: A
COMPARATIVE, RETROSPECTIVE, CROSS-SECTIONAL STUDY USING
NAMCS AND NHAMCS DATABASES
Mattoo PD, Pal S
St. John’s University, Jamaica, NY, USA
OBJECTIVES: The purpose of this study was to determine the extent of use, during
pregnancy, of medication(s) containing the active pharmaceutical ingredient(s) (API) 
classiﬁ ed to be teratogenic by the FDA. METHODS: This retrospective study analyzed 
the two 2005 cross-sectional databases of the National Ambulatory Medical Care
Survey (NAMCS) and the outpatient (OPD) section of the National Hospital Ambula-
tory Medical Care Survey (NHAMCS). Pregnant women who were prescribed terato-
genic APIs categorized by FDA as X or D were included in the study. The un-weighted 
data from NAMCS and NHAMCS were used to compute the Chi-square test statistics. 
RESULTS: Of 2,228 pregnancy related ambulatory visits, 22.94% were physician-
ofﬁ ce (PO) visits, and 77.06% were OPD visits. Medications were prescribed during
63.5% of the ambulatory visits. Category-X and/or D APIs were prescribed during
131 of these visits, comprising of 74.81% PO-visits and 25.19% OPD-visits. Chi-
square analysis between the number of visits [when APIs with Risk Categories (X, D, 
and X-and-D) were prescribed] and the trimester was signiﬁ cant (p  0.021) among 
PO-visits, but not signiﬁ cant among OPD-visits. During the PO-visits, Category-D 
APIs were most frequently prescribed in the 3rd trimester, while Category-X APIs were 
only prescribed in the 1st trimester. During the 131 visits, 158 Category-X and/or D 
APIs were prescribed, with 70.9% prescribed during PO-visits, and 29.1% during 
OPD-visits. Chi-square analysis between the number of APIs [with Risk Categories] 
and the trimester, was signiﬁ cant (p  0.025) among OPD-visits but not signiﬁ cant 
among PO-visits. During OPD-visits, the numbers of Category-X and Category-D 
APIs prescribed increased with the progression of the pregnancy. CONCLUSIONS:
This study showed that APIs with teratogenic effect were prescribed to pregnant 
women, particularly during 3rd trimester, with Category-D prescriptions being more 
than that of Category-X. A greater number of Category-D and X prescriptions was 
written during hospital-visits than physician-ofﬁ ce visits.
PIH51
RACIAL/ETHNIC DISPARITIES IN PRESCRIPTION DRUG USE AMONG 
OLDER ADULTS IN THE UNITED STATES
Qato D, Lindau ST, Conti R, Alexander GC
University of Chicago, Chicago, IL, USA
OBJECTIVES: We sought to examine racial and ethnic disparities in prescription drug
use among the U.S. older adult population. METHODS: The National, Social life,
Health and Aging Project (NSHAP) was used for this analysis. NSHAP is a nationally 
representative probability sample of 3,005 community-dwelling persons 57 to 85 years
of age from households across the United States. Household interviews were con-
ducted between July 2005 and March 2006. Multivariate logistic regression was used 
to examine the factors associated with differences in prescription medication use 
among non-Hispanic whites (Whites), non-Hispanic blacks (Blacks), and Hispanics
(any race). RESULTS: In unadjusted analyses, in comparison to Whites, the use of at
least one prescription medication was similar in Blacks (odds ratio [OR] 1.15, 95%
conﬁ dence intervals [CI] 0.80, 1.57), but signiﬁ cantly less among Hispanics (OR 0.49, 
CI 0.38, 0.73). After adjusting for demographic and health-related characteristics
including diagnosed medical conditions, Whites were signiﬁ cantly more likely to be 
using a prescription medication than either Blacks (OR 0.68, CI 0.49, 0.94) or Hispan-
ics (OR 0.52, CI 0.37, 0.73). Racial/ethnic disparities for Hispanics were signiﬁ cantly 
reduced (OR 0.73, CI 0.47, 1.14) after accounting for insurance status and usual 
source of care, and racial/ethnic disparities varied by therapeutic drug class. CON-
CLUSIONS: These data provide updated, nationally representative estimates of racial 
and ethnic differences in prescription medication use among community dwelling 
elders. hile differences in demographic and health characteristics did not explain the 
observed disparities in prescription drug use for blacks, socio-economic and access to 
care disparities may. However, differences in access to care were more important for 
Hispanics. In addition, differences in the use of over-the-counter drugs and dietary
supplements is also evident.
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TARGETED COMMUNITY OUTREACH REDUCES OUT-OF-POCKET 
PRESCRIPTION DRUG COSTS OF MEDICARE PART D BENEFICIARIES
Stebbins MR1, Patel RA2, Cutler TW1, Smith AR1, Shimomura S3, Patel V4, Tsunoda SM5, 
Mallari J6, Mirzaian E7, Lipton HL1
1University of California, San Francisco, San Francisco, CA, USA, 2University of the Paciﬁ c, 
Stockton, CA, USA, 3Western University of Health Sciences, Pomona, CA, USA, 4Touro
University – California, Vallejo, CA, USA, 5University of California, San Diego, La Jolla, CA, 
USA, 6Loma Linda University, Loma Linda, CA, USA, 7University of Southern California, Los
Angeles, CA, USA
OBJECTIVES: Given the complexity of the Medicare Part D prescription drug beneﬁ t
and annual plan changes, many Medicare beneﬁ ciaries often lack knowledge and skills
needed to select an optimal Part D plan. Through community outreach events targeted
toward underserved populations, we sought to minimize beneﬁ ciaries’ out-of-pocket
(OOP) prescription drug costs. We also examined the relationship between additional 
governmental assistance and potential OOP cost savings. METHODS: Students from 
seven California Schools of Pharmacy were trained to provide one-on-one Part D 
counseling, under faculty supervision. Students obtained the 2009 annual estimated 
costs for each participant’s current stand-alone prescription drug plan (PDP), and 
compared these costs to the lowest-cost plan (if different), using the online Medicare
Prescription Drug Plan Finder tool. Additionally, each participant’s current plan cost
ranking was compared to the 51 PDPs offered in California (2009) and recorded along 
with subsidy status. RESULTS: During 43 statewide outreach events, pharmacy stu-
dents counseled 661 beneﬁ ciaries enrolled in a PDP, of whom 519 (79%) were receiv-
ing governmental assistance with their prescription medication costs (i.e., Medicaid 
or the low-income subsidy). Beneﬁ ciaries were, on average, enrolled in the 12th-
lowest-cost plan (out of 51) in terms of OOP plan costs, and 496 (75%) beneﬁ ciaries 
had potential OOP savings by switching to a lower-cost plan. Those receiving a
subsidy had a lower annual mean OOP potential cost savings than non-subsidized 
beneﬁ ciaries ($399 vs. $587, p  0.0001). However, they had a higher mean percentage
of potential cost-savings relative to the annual cost of their current plan (51% vs. 
32%, p  0.0001). CONCLUSIONS: More than three-fourths of the beneﬁ ciaries in 
this study were not in the PDP with the lowest OOP medications costs. Our data 
suggest that Medicare beneﬁ ciaries, regardless of income, can optimize their prescrip-
tion drug plan choices through outreach interventions conducted by pharmacy stu-
dents with Part D expertise.
PIH53
IS MEDICARE PART D PLAN BENEFIT DESIGN ASSOCIATED WITH
COST-RELATED NONADHERENCE TO PRESCRIPTION DRUGS? AN
ANALYSIS USING THE MEDICARE CAHPS DATA
Wei II, Howell BL, Frankenﬁ eld DL, Anderson KK, Sekscenski E
Centers for Medicare & Medicaid Services, Baltimore, MD, USA
OBJECTIVES: Cost-related nonadherence to prescription drugs (CRN) can result in
unfavorable health conditions. The objective of this study was to examine the relation-
ship between CRN and elements in Part D plan beneﬁ t design. METHODS: This 
was a cross-sectional study using the 2006 Medicare Consumer Assessment of 
Healthcare Providers and Systems (CAHPS) data. We augmented the CAHPS data 
with the Centers for Medicare & Medicaid Services (CMS) plan beneﬁ t design infor-
mation, CMS Hierarchical Condition Category scores and a composite socioeconomic 
indicator derived from U.S. Census data. We examined the relationship using survey
logistic modeling. Our analytic data included survey respondents enrolled in a stand-
alone prescription drug plan (PDP) or Medicare Advantage drug plan (MA-PD) in
2006. Individuals who were identiﬁ ed by CMS as having other creditable drug cover-
age, deemed low-income subsidy, or enrolling in MA cost plans were excluded. 
RESULTS: About one-quarter (weighted percentage) of the study sample (unweighted 
N  133,616; weighted N  11,008,931) was enrolled in an MA-PD. Overall, 24 %
of the sample enrolled in a plan with drug deductibles, 87% had tiered copayments, 
59% were in plans requiring prior authorization or step therapy for eight or more 
of the top 100 drugs, and 94% offered mailorder services. After adjusting for 
other variables, we found MA-PD enrollment was associated with higher reported
CRN compared with PDP enrollment. Additionally, plans with drug deductibles, 
tiered copayments, or mailorder services, were also associated with higher reported 
CRN (OR [95% CI]  1.12 [1.03–1.21], 1.21 [1.04–1.39], 1.24 [1.06–1.46], respec-
tively). Plans requiring prior authorization or step therapy for eight or more of the
top 100 drugs did not present increased risk for CRN. CONCLUSIONS: Medicare 
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beneﬁ ciaries who were enrolled in an MA-PD or a drug plan with drug deductibles, 
tiered copayments, or mailorder services in the plan beneﬁ t design were more likely 
to experience CRN.
PIH54
HEALTH CARE UTILIZATION AND COSTS AMONGST WOMEN WITH
FEMALE SEXUAL DYSFUNCTION (FSD) AND HYPOACTIVE SEXUAL
DESIRE DISORDER (HSDD)
Foley K1, Foley D2, Shah H3
1Thomson Reuters, Philadelphia, PA, USA, 2Boehringer Ingelheim Ltd, Ridgeﬁ eld, CT, USA, 
3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgeﬁ eld, CT, USA
OBJECTIVES: The health care utilization and costs among commercially insured 
women with a diagnosis of Female Sexual Dysfunction (FSD) and Hypoactive Sexual 
Desire Disorder (HSDD) in the United States. METHODS: The Thomson Reuters
Marketscan Database was used to identify women aged 18–64 with an ICD-9-CM 
coded diagnosis of FSD, including a subset with HSDD from January 1, 1998-Sep-
tember 30, 2006. A control group of women with no diagnosis of any sexual dysfunc-
tion was matched 3:1 to cases based on age, health plan and enrollment period.
Controls were assigned the index date of their matched case. Health care utilization 
and costs were examined in the year prior (“pre-period”) to and following index 
(“post-period”). RESULTS: A total of 4831 women were coded as FSD (59% as
HSDD) and matched to 14,493 controls. The FSD group had more outpatient visits
and services in both the pre- (22.2 vs. 16.2, p  0.001) and post- (25.4 vs. 17.7, p 
0.001) periods compared with their matched controls. They also consistently ﬁ lled 
more prescriptions in the pre- (14.5 vs. 11.5, p  0.001) and post- (16.2 vs. 7.2, p 
0.001) periods. Nearly identical patterns were observed in the HSDD group. These 
higher levels of utilization resulted in costs that were higher for FSD and HSDD 
women relative to their matched controls in the pre-period ($1296 and $ 1146 respec-
tively). Similar patterns of increased health care utilization were also seen in the post-
period for both FSD and HSDD patients ($1,190 and $897 respectively). The most
signiﬁ cant drivers of health care costs for both groups were outpatient medical services
(including professional visits, outpatient surgeries, and laboratory expenditures) and
total prescription medication costs. CONCLUSIONS: Women diagnosed with FSD
and HSDD use signiﬁ cantly more health care services than women without diagnosed 
sexual dysfunction. The resulting higher costs are driven by a greater use of outpatient 
services and prescription medications.
PIH56
CARESS: THE CANADIAN REGISTRY OF SYNAGIS‚ SUMMARY OF
2006–2008 RSV SEASONS
Paes B1, Reim EK2, Lanctôt KL2, Mitchell I3
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, 
ON, Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: To understand current management (utilization, compliance) with
palivizumab prophylaxis of children at high-risk of RSV infection in Canada. 
METHODS: A prospective, observational, registry of infants at high risk for RSV who
received at least one dose of palivizumab during the 2006 to 2008 RSV seasons from 
24 sites. Neonatal and demographic data were collected upon enrollment. Data on
palivizumab utilization and compliance, including outcomes related to a respiratory 
infection were collected monthly until the full course of palivizumab was completed
or at the end of the relevant RSV season. RESULTS: A total of 2910 infants were
enrolled, age two days to 47 months (mean  5.5 months). In total, 54.4% were male, 
62.2% Caucasian, average gestational age (GA) was 32.0 o 6.8 completed weeks.
2079 (71.4%) infants received palivizumab because they were premature only (i.e.
a35 completed weeks GA), 255 (8.8%) required oxygen, 288 (9.9%) had congenital 
heart disease and 288 (9.9%) were prophylaxed for other risk factors such as CNS
disorders, airway anomalies and cystic ﬁ brosis. Compliance was high; 77.8% received 
at least four injections of palivizumab between September and June each season.
Overall 12, 973 doses were given. No directly related serious adverse events were
identiﬁ ed. A total of 159 infants had 194 hospitalizations for respiratory tract infec-
tions (hospitalization rate 5.5%) and rates were highest in those with chronic lung 
disease (9.8%, p  0.006). The RSV positive hospitalization rate was only 0.96%. 
CONCLUSIONS: The RSV hospitalization rate observed in the 2006–2008 RSV
seasons was lower than that found in several published reports (range1.3%–5.3%). 
The rates of RSV hospitalization may be decreasing for various reasons such as high
compliance with palivizumab prophylaxis, variability in RSV epidemiology, hospital
admission criteria and preventive education.
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PMH1
ALPRAZOLAM-RELATED DEATHS IN WEST VIRGINIA
Shah N, Smith MJ, Abate MA
West Virginia University, Morgantown, WV, USA
OBJECTIVES: Alprazolam is a frequently prescribed benzodiazepine associated with 
abuse and misuse that can lead to fatalities. This study’s aims were to: 1) describe the 
characteristics of alprazolam-related death cases; 2) describe the comorbidities, co-
ingested drugs, and mean alprazolam concentrations of decedents; and 3) compare
characteristics between alprazolam and non alprazolam-related death cases.
METHODS: Data from all drug-related deaths in West Virginia from January 1,
2005 to November 16, 2007 were extracted from the Forensic Drug Database. Chi 
square tests compared categorical descriptive statistics between alprazolam and non-
alprazolam cases. One-way ANOVA compared mean alprazolam blood concentra-
tions based upon numbers of other ingested drugs. RESULTS: Of the 1199 drug-related 
deaths in the database, alprazolam was a contributing cause in 204 (17.0%) cases. It 
was involved in an increasing number of drug-related deaths over time. The mean age 
of alprazolam cases was 39.6 (11.2) years; most were male (66.3%) and white 
(96.0%), with the deaths ruled accidental (90.2%). There was a prescription for
alprazolam in over half the cases (52.5%); approximately one-third (33.8%) had a
history of substance abuse or cardiovascular disease. At least one other drug was a 
contributor to death in 97.5% of the alprazolam cases, with an opiate detected in 
most cases (88.7%). The mean alprazolam blood concentration was signiﬁ cantly 
higher when taken alone than when ingested with one or more drugs (p  0.001). 
More alprazolam decedents were obese (43.9%) compared to non-alprazolam dece-
dents (32.9%) (p  0.005). Alprazolam cases had a signiﬁ cantly greater average
number of drugs implicated in death (2.9  1.0) than non-alprazolam cases (2.3  1.3) 
(p  0.001). CONCLUSIONS: Alprazolam-associated deaths are a signiﬁ cant public 
health problem in West Virginia; these cases have characteristics that can differ from
other drug death cases. Certain drug combinations involving alprazolam may pose a 
greater risk for serious adverse events.
PMH2
USE OF HYPNOTICS/ANXIOLYTICS IN PATIENTS WITH MAJOR
DEPRESSIVE DISORDER: ASSOCIATIONS WITH CHRONIC PAIN, SLEEP
DISORDERS, AND ANTIDEPRESSANT SELECTION
Liu X1, Ye W2, Wohlreich M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA
OBJECTIVES: Many patients with major depressive disorder (MDD) suffer from
chronic pain (CP) and sleep disturbances (SD). Little is known about associations
between the use of hypnotics/anxiolytics for these conditions and the use of antidepres-
sants in real-world clinical settings. This study examined the use of hypnotics and 
anxiolytics, their associations with CP and SD, and initiation of serotonin-norepineph-
rine reuptake inhibitors (duloxetine and venlafaxine XR) in a large managed-care 
population of patients with MDD. METHODS: A total of 153,913 patients who had
at least 1 diagnosis of MDD during the year 2006 were selected from a large com-
mercially insured administrative claims database. The analytic sample consisted of 
47,109 (30.6%) males and 106,804 (69.4%) females, with a mean age of 43.6 years
(SD  12.7). In accordance with ICD-9-CM, CP was deﬁ ned as any pain of the fol-
lowing 6 categories: headache, rheumatoid arthritis, osteoarthritis, low back pain, 
ﬁ bromyalgia, and neuropathic pain. Hypnotics/anxiolytics were classiﬁ ed into 3 cate-
gories: benzodiazepines (BENZ), non-benzodiazepine hypnotics (NBENZH), and non-
benzodiazepine anxiolytics (NBENZA). RESULTS: Of the 153,913 patients with 
MDD, 35.5% had CP; 5.3%, SD; and 7.3%, CP plus SD. Over the 1-year study
period, 33.1% of patients were prescribed BENZ; 16.9%, NBENZH; and 6.1%,
NBENZA. Of patients with MDD, patients also diagnosed with CP and SD were most 
frequently prescribed NBENZH, BENZ, and NBENZA (36.4%, 47.7%, 9.6%), fol-
lowed by patients with SD (30.2%, 36.7%, 6.4%), CP (18.7%, 39.9%, 7.4%), and 
MDD only (11.6%, 26.1%, 4.6%). Prior use of BENZ (OR  1.5, 95% CI  1.4–1.6), 
NBENZH (OR  1.6, 95% CI  1.5–1.7), and NBENZA (OR  1.2, 95% CI  1.1–
1.3) was signiﬁ cantly associated with initiation of duloxetine compared with venla-
faxine XR. CONCLUSIONS: Hypnotics and anxiolytics are commonly used in MDD
patients. CP and SD are associated with increased use of hypnotics and anxioloytics 
in MDD patients. Prior use of hypnotics and anxioloytics may be associated with
antidepressant selection.
PMH3
DEPRESSION: ETHNIC DIFFERENCES IN PREVALENCE, DIAGNOSIS, 
AND SYMPTOMS
Kannan H, Bolge SC, Wagner S
Consumer Health Sciences International, Princeton, NJ, USA
OBJECTIVES: To assess ethnic differences in the prevalence, physician diagnosis and 
symptomology of depression. METHODS: Data were taken from the 2008 US
National Health and Wellness Survey (NHWS), a self-reported, Internet-based study
of the disease status, attitudes, habits, and outcomes of adults age 18. Ethnic groups 
included whites, blacks, Hispanics and Asians. Respondents self reported experiencing 
depression, depression diagnosed by a physician, and experiencing the following in 
the previous month: bothered by feeling down, depressed, or hopeless; bothered by 
having little interest or pleasure in doing things. Prevalence was calculated using fre-
quency weights based on age, gender and race. Chi-square analyses were conducted 
to assess statistically signiﬁ cant differences. RESULTS: Of the 61,016 respondents,
22.2% (Projected 53.8M; 25%) reported experiencing depression within the previous 
year. There were signiﬁ cant (p  0.05) variations across ethnic groups: White  39.5M, 
25.8%; Black  4.9M, 19.8%; Hispanic  8.1M, 27.6%; Asian  1.3M, 16.1%). 
Among those who report experiencing depression, whites were most likely to be
diagnosed (77.0%) compared with 60.8% of blacks, 62.8% of Hispanics, and only
48.4% of Asians, who were least likely to be diagnosed. Among those who did not
self-report experiencing depression, 11.2% of whites, 12.8% of blacks, 13.1% of 
Hispanics, and 13.46% of Asians experienced one depression symptom and 9.6% of 
whites, 11.9% of blacks, 13.2% of Hispanics, and 12.2% of Asians experienced both
depression symptoms (p  0.05). CONCLUSIONS: While there is signiﬁ cant ethnic 
variation in prevalence of self-reported depression, there is even greater ethnic varia-
tion in diagnosis among patients experiencing depression. Also, recognition of symp-
